Ascend Capital’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History
Bought
Maintained
Sold
Other funds holding LKFT
BBA
Ascend Capital's LKFT Position: Q2 2018 in Review
Ascend Capital sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q2 2018, closing a stake of 25,063 shares — an estimated $2.5M sold.
Ascend Capital first reported a position in LKFT in Q2 2017 and held it in 2 quarters. The position peaked at $5.66M in Q2 2017. 79 funds tracked by Wall St. Rank hold LKFT as of Q2 2018.
- Ascend Capital reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q2 2018 after selling out during the quarter.
- Ascend Capital sold 25,063 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2018, an estimated $2.5M.
- Ascend Capital first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q2 2017 and held it in 2 quarters.
- Ascend Capital's Lakefront Biotherapeutics American Depositary Shares position peaked at $5.66M in Q2 2017.
- 79 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2018.
Based on Ascend Capital's 13F filing for Q2 2018, filed 13 Aug 2018.